Ceramic coating and method of preparation thereof
A ceramic coating with gradient density/porosity and/or incorporated biologically active agents can be fabricated on the surface of substrates, including the surface of implantable medical devices.
1. A coated substrate, comprising:
a gradient ceramic coating, wherein the gradient ceramic coating is prepared by exposing a portion of a substrate to an aqueous system, wherein the exposing is performed at a temperature of about 20° C. to about 100° C.;
wherein the aqueous system comprises water, Ca2+, Mg2+, Na+, K+, Cl—, SO42-, HPO42-, HCO3- and a buffer system; and
wherein the aqueous system has an initial pH of about 5.5 to about 7.5; and
the gradient ceramic coating has a density of about 75 to about 90% closest to the substrate and a density of about 35 to about 60% at the gradient ceramic coating surface as determined by scanning electron microscope.
2. The coated substrate of claim 1 , wherein the buffer system comprises 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid salts, tris-hydroxymethyl aminomethan, piperazine-1,4-bis(2-ethanesulfonic acid), piperazine-1,4-bis(2-ethanesulfonic acid) salts, or combinations thereof.
3. The coated substrate of claim 1 , wherein the gradient ceramic coating has a total thickness of about 5 micrometers to about 50 micrometers.
4. The coated substrate of claim 1 , wherein the coated substrate is an implantable medical device.
5. A coated substrate, comprising:
a ceramic coating comprising a biologically active agent, wherein the ceramic coating is prepared by exposing a portion of a substrate to an aqueous system, wherein the exposing is performed at a temperature of about 20° C. to about 100° C.;
wherein the aqueous system comprises water, Ca2+, Mg2+, Na+, K+, Cl—, SO42-, HPO42-, HCO3-, a buffer system and a biologically active agent; and
wherein the aqueous system has an initial pH of about 5.5 to about 7.5,
wherein during the exposing, a ratio of aqueous system volume to substrate surface area is about 1 mm to about 50 mm.
6. The coated substrate of claim 5 , wherein the buffer system comprises 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid salts, tris-hydroxymethyl aminomethan, piperazine-1,4-bis(2-ethanesulfonic acid), piperazine-1,4-bis(2-ethanesulfonic acid) salts, or combinations thereof.
7. The coated substrate of claim 5 , wherein the following are present in the aqueous system:
Ca2+ is present in an amount of about 2.5 to about 15.0 mM;
Mg2+ is present in an amount of about 0.5 to about 5.0 mM;
Na+ is present in an amount of about 50.0 to about 300.0 mM;
K+ is present in an amount of about 2.0 to about 20.0 mM;
Cl— is present in an amount of about 50.0 to about 350.0 mM;
SO42- is present in an amount of about 0 to about 2.0 mM;
HPO42- is present in an amount of about 1.0 to about 10.0 mM; and
HCO3- is present in an amount of about 10.0 to about 150.0 mM.
8. The coated substrate of claim 5 , wherein the coated substrate is an implantable medical device.
9. The coated substrate of claim 7 , wherein the initial pH of the aqueous system is about 6.20 to about 6.38.
10. The coated substrate of claim 5 , wherein the incorporation efficiency of the biologically active agent in the coating is about 50 to about 100%.
11. The coated substrate of claim 5 , wherein the ratio of aqueous system volume to substrate surface area is about 10 mm to about 40 mm.